INO Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.366

-39%

-0.370

-27.45%

-0.277

-54.64%

Estimates Revision

The market is revising Downward the revenue expectations for Inovio Pharmaceuticals, Inc. (INO) for FY2025, with the revenue forecasts being adjusted by -6.6% over the past three months. During the same period, the stock price has changed by -40.00%.

Revenue Estimates for FY2025

Revise Downward

-6.6%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+18.48%

In Past 3 Month

Stock Price

Go Down

-40.00%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast INO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INO is 7.33 USD with a low forecast of 3.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

1 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

3.00

Averages

7.33

High

13.00

Current: 0.000

Low

3.00

Averages

7.33

High

13.00

Piper Sandler

Edward Tenthoff

Overweight

maintain

$5 -> $6

2025-11-14

Reason

Piper Sandler

Edward Tenthoff

Price Target

$5 -> $6

2025-11-14

maintain

Overweight

Reason

Piper Sandler analyst Edward Tenthoff raised the firm's price target on Inovio to $6 from $5 and keeps an Overweight rating on the shares. The firm notes the company ended Q3 with cash of $50.8M and subsequently raised gross proceeds of $28.75M bringing pro forma cash to $77.3M, expected to fund operations into Q3 2026 through INO-3107 approval.

Piper Sandler

Edward Tenthoff

initiated

2025-07-09

Reason

Piper Sandler

Edward Tenthoff

Price Target

2025-07-09

initiated

Reason

Piper Sandler analyst Edward Tenthoff initiated coverage of Inovio with an Overweight rating and $5 price target. The company is is developing DNA-encoded medicines to treat cancer, infectious and rare diseases, the analyst tells investors in a research note. The firm says INO-3107, being developed to treat recurrent respiratory papillomatosis caused by human papillomavirus, was well tolerated and achieved robust clinical efficacy in a Phase I/II study.

Oppenheimer

Outperform

downgrade

$15 -> $13

2025-05-14

Reason

Oppenheimer

Price Target

$15 -> $13

2025-05-14

downgrade

Outperform

Reason

Oppenheimer lowered the firm's price target on Inovio to $13 from $15 and keeps an Outperform rating on the shares. The firm notes the company reported Q1 2025 results with $25.1M OpEx and cash balance of $68.4M, which is expected to provide runway into Q1 2026. Encouragingly, Inovio remains on track to initiate rolling BLA submission for INO-3107 in mid-2025, and subsequent filing completion in the second half of 2025 could support potential approval as early as mid-2026 if granted priority review, Oppenheimer adds.

HC Wainwright & Co.

Raghuram Selvaraju

Hold

Reiterates

2025-03-19

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

2025-03-19

Reiterates

Hold

Reason

RBC Capital

Gregory Renza

Hold

Maintains

$6 → $5

2025-03-19

Reason

RBC Capital

Gregory Renza

Price Target

$6 → $5

2025-03-19

Maintains

Hold

Reason

RBC Capital lowered the firm's price target on Inovio to $5 from $6 and keeps a Sector Perform rating on the shares. The company continues to drive steady advancement of its diverse pipeline in the background, but attention remains squarely on the RRP opportunity, commercial setup, and Inovio's ability to execute, the analyst tells investors in a research note. RBC adds however that its reduced price target reflects the one-year cash runway for 3107's critical though risky path.

Citizens Capital Markets

Roy Buchanan

Buy

Reiterates

$18

2025-03-14

Reason

Citizens Capital Markets

Roy Buchanan

Price Target

$18

2025-03-14

Reiterates

Buy

Reason

Valuation Metrics

The current forward P/E ratio for Inovio Pharmaceuticals Inc (INO.O) is -1.33, compared to its 5-year average forward P/E of -2.95. For a more detailed relative valuation and DCF analysis to assess Inovio Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.95

Current PE

-1.33

Overvalued PE

-0.44

Undervalued PE

-5.46

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.71

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

1.18

Undervalued EV/EBITDA

-4.59

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

400.22

Current PS

36.67

Overvalued PS

864.26

Undervalued PS

-63.82

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

INO News & Events

Events Timeline

No data

News

7.0

01-08PRnewswire

Inovio Pharmaceuticals Faces Investigation as Stock Plummets 24.45%

7.0

2025-12-30Globenewswire

Inovio Pharmaceuticals Faces 24.45% Stock Drop After FDA Rejects Accelerated Approval for INO-3107

9.0

2025-12-29Benzinga

Ultragenyx Shares Plunge 42% Following Phase 3 Study Failures for Setrusumab

People Also Watch

Frequently Asked Questions

What is Inovio Pharmaceuticals Inc (INO) stock price today?

The current price of INO is 1.59 USD — it has decreased -1.24 % in the last trading day.

What is Inovio Pharmaceuticals Inc (INO)'s business?

Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.

What is the price predicton of INO Stock?

What is Inovio Pharmaceuticals Inc (INO)'s revenue for the last quarter?

Inovio Pharmaceuticals Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Inovio Pharmaceuticals Inc (INO)'s earnings per share (EPS) for the last quarter?

Inovio Pharmaceuticals Inc. EPS for the last quarter amounts to -0.87 USD, decreased -2.25 % YoY.

What changes have occurred in the market's expectations for Inovio Pharmaceuticals Inc (INO)'s fundamentals?

How many employees does Inovio Pharmaceuticals Inc (INO). have?

Inovio Pharmaceuticals Inc (INO) has 134 emplpoyees as of January 09 2026.

What is Inovio Pharmaceuticals Inc (INO) market cap?

Today INO has the market capitalization of 110.61M USD.